| Variable . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . |
|---|---|---|---|
| Total index drug induction costs (unweighted),a US$ | |||
| Mean, SD | 13,319.54 (3475.08) | 16,043.60 (13,940.66) | 16,061.70 (4599.57) |
| Median (Q1, Q3) | 13,307.78 (12,525.31, 14,194.55) | 12,569.26 (9385.18, 17,763.38) | 16,444.32 (14,437.34, 18,097.00) |
| Min, max | (0, 61,485.77) | (0, 134,019.00) | (0, 36,324.64) |
| Index drug induction costs per patient per month,a US$ | |||
| Mean, SD | 11,555.14 (4560.16) | 4232.04 (3688.56) | 4497.38 (1545.20) |
| Median (Q1, Q3) | 12,060.67 (8567.84, 14,555.15) | 3401.65 (2487.15, 4736.14) | 4732.32 (3799.27, 5419.01) |
| Min, max | (0, 48,954.98) | (0, 41,368.11) | (0, 11,212.45) |
| Total other pharmacy costs (unweighted),b US$ | |||
| Mean, SD | 4524.15 (5391.86) | 4335.29 (4826.57) | 6376.92 (8561.13) |
| Median (Q1, Q3) | 3457.16 (950.33, 6421.62) | 2899.6 (760.47, 6475.97) | 4593.85 (1165.11, 8761.25) |
| Min, max | (0, 87,198.20) | (0, 46,823.48) | (0, 108,755.62) |
| Other pharmacy costs per patient per month,b US$ | |||
| Mean, SD | 636.96 (754.00) | 445.04 (504.69) | 669.72 (902.92) |
| Median (Q1, Q3) | 481.25 (135.45, 909.61) | 298.02 (81.14, 668.00) | 480.94 (108.59, 936.45) |
| Min, max | (0, 11,935.50) | (0, 5,113.39) | (0, 11,834.02) |
| Cost of first maintenance dose, US$ | |||
| Mean, SD | 2159.03 (356.90) | 5503.43 (3822.84) | 5849.18 (1334.74) |
| Median (Q1, Q3) | 2209.36 (2105.65, 2340.32) | 4626.48 (3578.40, 6044.66) | 5954.36 (5502.03, 6354.35) |
| Min, max | (0, 5,107.30) | (0, 41,531.01) | (12, 14,774.68) |
| Cost per mg, US$ | |||
| Mean, SD | 53.98 (8.92) | 10.48 (7.28) | 19.50 (4.45) |
| Median (Q1, Q3) | 55.23 (52.64, 58.51) | 8.81 (6.82, 11.51) | 19.85 (18.34, 21.18) |
| Min, max | (0, 127.68) | (0, 79.11) | (0.04, 49.25) |
| Variable . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . |
|---|---|---|---|
| Total index drug induction costs (unweighted),a US$ | |||
| Mean, SD | 13,319.54 (3475.08) | 16,043.60 (13,940.66) | 16,061.70 (4599.57) |
| Median (Q1, Q3) | 13,307.78 (12,525.31, 14,194.55) | 12,569.26 (9385.18, 17,763.38) | 16,444.32 (14,437.34, 18,097.00) |
| Min, max | (0, 61,485.77) | (0, 134,019.00) | (0, 36,324.64) |
| Index drug induction costs per patient per month,a US$ | |||
| Mean, SD | 11,555.14 (4560.16) | 4232.04 (3688.56) | 4497.38 (1545.20) |
| Median (Q1, Q3) | 12,060.67 (8567.84, 14,555.15) | 3401.65 (2487.15, 4736.14) | 4732.32 (3799.27, 5419.01) |
| Min, max | (0, 48,954.98) | (0, 41,368.11) | (0, 11,212.45) |
| Total other pharmacy costs (unweighted),b US$ | |||
| Mean, SD | 4524.15 (5391.86) | 4335.29 (4826.57) | 6376.92 (8561.13) |
| Median (Q1, Q3) | 3457.16 (950.33, 6421.62) | 2899.6 (760.47, 6475.97) | 4593.85 (1165.11, 8761.25) |
| Min, max | (0, 87,198.20) | (0, 46,823.48) | (0, 108,755.62) |
| Other pharmacy costs per patient per month,b US$ | |||
| Mean, SD | 636.96 (754.00) | 445.04 (504.69) | 669.72 (902.92) |
| Median (Q1, Q3) | 481.25 (135.45, 909.61) | 298.02 (81.14, 668.00) | 480.94 (108.59, 936.45) |
| Min, max | (0, 11,935.50) | (0, 5,113.39) | (0, 11,834.02) |
| Cost of first maintenance dose, US$ | |||
| Mean, SD | 2159.03 (356.90) | 5503.43 (3822.84) | 5849.18 (1334.74) |
| Median (Q1, Q3) | 2209.36 (2105.65, 2340.32) | 4626.48 (3578.40, 6044.66) | 5954.36 (5502.03, 6354.35) |
| Min, max | (0, 5,107.30) | (0, 41,531.01) | (12, 14,774.68) |
| Cost per mg, US$ | |||
| Mean, SD | 53.98 (8.92) | 10.48 (7.28) | 19.50 (4.45) |
| Median (Q1, Q3) | 55.23 (52.64, 58.51) | 8.81 (6.82, 11.51) | 19.85 (18.34, 21.18) |
| Min, max | (0, 127.68) | (0, 79.11) | (0.04, 49.25) |
Abbreviations: max, maximum; min, minimum; Q1, quarter 1; Q3, quarter 3; SD, standard deviation.
aBetween index date 1 and index date 2 (not inclusive of index date 2).
bSix months before index date 1 and index date 2 (not inclusive of index date 2).
| Variable . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . |
|---|---|---|---|
| Total index drug induction costs (unweighted),a US$ | |||
| Mean, SD | 13,319.54 (3475.08) | 16,043.60 (13,940.66) | 16,061.70 (4599.57) |
| Median (Q1, Q3) | 13,307.78 (12,525.31, 14,194.55) | 12,569.26 (9385.18, 17,763.38) | 16,444.32 (14,437.34, 18,097.00) |
| Min, max | (0, 61,485.77) | (0, 134,019.00) | (0, 36,324.64) |
| Index drug induction costs per patient per month,a US$ | |||
| Mean, SD | 11,555.14 (4560.16) | 4232.04 (3688.56) | 4497.38 (1545.20) |
| Median (Q1, Q3) | 12,060.67 (8567.84, 14,555.15) | 3401.65 (2487.15, 4736.14) | 4732.32 (3799.27, 5419.01) |
| Min, max | (0, 48,954.98) | (0, 41,368.11) | (0, 11,212.45) |
| Total other pharmacy costs (unweighted),b US$ | |||
| Mean, SD | 4524.15 (5391.86) | 4335.29 (4826.57) | 6376.92 (8561.13) |
| Median (Q1, Q3) | 3457.16 (950.33, 6421.62) | 2899.6 (760.47, 6475.97) | 4593.85 (1165.11, 8761.25) |
| Min, max | (0, 87,198.20) | (0, 46,823.48) | (0, 108,755.62) |
| Other pharmacy costs per patient per month,b US$ | |||
| Mean, SD | 636.96 (754.00) | 445.04 (504.69) | 669.72 (902.92) |
| Median (Q1, Q3) | 481.25 (135.45, 909.61) | 298.02 (81.14, 668.00) | 480.94 (108.59, 936.45) |
| Min, max | (0, 11,935.50) | (0, 5,113.39) | (0, 11,834.02) |
| Cost of first maintenance dose, US$ | |||
| Mean, SD | 2159.03 (356.90) | 5503.43 (3822.84) | 5849.18 (1334.74) |
| Median (Q1, Q3) | 2209.36 (2105.65, 2340.32) | 4626.48 (3578.40, 6044.66) | 5954.36 (5502.03, 6354.35) |
| Min, max | (0, 5,107.30) | (0, 41,531.01) | (12, 14,774.68) |
| Cost per mg, US$ | |||
| Mean, SD | 53.98 (8.92) | 10.48 (7.28) | 19.50 (4.45) |
| Median (Q1, Q3) | 55.23 (52.64, 58.51) | 8.81 (6.82, 11.51) | 19.85 (18.34, 21.18) |
| Min, max | (0, 127.68) | (0, 79.11) | (0.04, 49.25) |
| Variable . | Adalimumab (n = 748) . | Infliximab (n = 688) . | Vedolizumab (n = 421) . |
|---|---|---|---|
| Total index drug induction costs (unweighted),a US$ | |||
| Mean, SD | 13,319.54 (3475.08) | 16,043.60 (13,940.66) | 16,061.70 (4599.57) |
| Median (Q1, Q3) | 13,307.78 (12,525.31, 14,194.55) | 12,569.26 (9385.18, 17,763.38) | 16,444.32 (14,437.34, 18,097.00) |
| Min, max | (0, 61,485.77) | (0, 134,019.00) | (0, 36,324.64) |
| Index drug induction costs per patient per month,a US$ | |||
| Mean, SD | 11,555.14 (4560.16) | 4232.04 (3688.56) | 4497.38 (1545.20) |
| Median (Q1, Q3) | 12,060.67 (8567.84, 14,555.15) | 3401.65 (2487.15, 4736.14) | 4732.32 (3799.27, 5419.01) |
| Min, max | (0, 48,954.98) | (0, 41,368.11) | (0, 11,212.45) |
| Total other pharmacy costs (unweighted),b US$ | |||
| Mean, SD | 4524.15 (5391.86) | 4335.29 (4826.57) | 6376.92 (8561.13) |
| Median (Q1, Q3) | 3457.16 (950.33, 6421.62) | 2899.6 (760.47, 6475.97) | 4593.85 (1165.11, 8761.25) |
| Min, max | (0, 87,198.20) | (0, 46,823.48) | (0, 108,755.62) |
| Other pharmacy costs per patient per month,b US$ | |||
| Mean, SD | 636.96 (754.00) | 445.04 (504.69) | 669.72 (902.92) |
| Median (Q1, Q3) | 481.25 (135.45, 909.61) | 298.02 (81.14, 668.00) | 480.94 (108.59, 936.45) |
| Min, max | (0, 11,935.50) | (0, 5,113.39) | (0, 11,834.02) |
| Cost of first maintenance dose, US$ | |||
| Mean, SD | 2159.03 (356.90) | 5503.43 (3822.84) | 5849.18 (1334.74) |
| Median (Q1, Q3) | 2209.36 (2105.65, 2340.32) | 4626.48 (3578.40, 6044.66) | 5954.36 (5502.03, 6354.35) |
| Min, max | (0, 5,107.30) | (0, 41,531.01) | (12, 14,774.68) |
| Cost per mg, US$ | |||
| Mean, SD | 53.98 (8.92) | 10.48 (7.28) | 19.50 (4.45) |
| Median (Q1, Q3) | 55.23 (52.64, 58.51) | 8.81 (6.82, 11.51) | 19.85 (18.34, 21.18) |
| Min, max | (0, 127.68) | (0, 79.11) | (0.04, 49.25) |
Abbreviations: max, maximum; min, minimum; Q1, quarter 1; Q3, quarter 3; SD, standard deviation.
aBetween index date 1 and index date 2 (not inclusive of index date 2).
bSix months before index date 1 and index date 2 (not inclusive of index date 2).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
